The myelodysplastic syndrome(s): A perspective and review highlighting current controversies

Leukemia Research

Volumn 27, Issue 2, 2003, Pages 95-120

  Steensma, David P ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute myelogenous leukemia; Disease classification; FAB; IPSS; Myelodysplastic syndrome; WHO

Indexed keywords

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; BIODIVERSITY; BLOOD DYSCRASIA; BONE MARROW DEPRESSION; BONE MARROW DISEASE; CYTOGENETICS; DISEASE COURSE; HEMATOPOIESIS; HUMAN; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STEM CELL; WORLD HEALTH ORGANIZATION;

COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TERMINOLOGY;

EID: 0037298128     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00098-X     Document Type: Review

References (388)

1. Sontag S. Illness as metaphor. New York: Farrar, Straus & Giroux, 1988.
2. Fleischman S. I am ..., I have ..., I suffer from ...: a linguist relfects on the language of illness and disease. J. Med. Human. 20:1999;3-32.
3. Wood M.L. Naming the illness: the power of words. Fam. Med. 23:1991;534-538.
4. Bagby G.C. Jr. The concept of preleukemia: clinical and laboratory studies [review] [123 references]. Crit. Rev. Oncol. Hematol. 4:1986;203-220.
5. Anonymous. Is preleukemic states an adequate designation? Blood Cells 1976;2:347-51.
6. Lichtman M.A. Language and the clonal myeloid diseases. Blood. 99:2002;725-726.
7. Tefferi A., Thibodeau S.N., Solberg L.A. Jr. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood. 75:1990;1770-1773.
8. Culligan D.J., Cachia P., Whittaker J., Jacobs A., Padua R.A. Clonal lymphocytes are detectable in only some cases of MDS. Br. J. Haematol. 81:1992;346-352.
9. White N.J., Nacheva E., Asimakopoulos F.A., Bloxham D., Paul B., Green A.R. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood. 83:1994;2809-2816.
10. Janssen J.W., Buschle M., Layton M., Drexler H.G., Lyons J., van den Berghe H.et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 73:1989;248-254.
11. Lawrence H.J., Broudy V.C., Magenis R.E., Olson S., Tomar D., Barton S.et al. Cytogenetic evidence for involvement of B lymphocytes in acquired idiopathic sideroblastic anemias. Blood. 70:1987;1003-1005.
12. Nilsson L., Astrand-Grundstrom I., Arvidsson I., Johansson B., Hokland P., Kjeldsen L.et al. Involvement of the lympho-myeloid stem cells in different cytogenetic subgroups of myelodysplastic syndromes. Leuk. Res. 25:2001;S2.
13. Kibbelaar R.E., van Kamp H., Dreef E.J., de Groot-Swings G., Kluin-Nelemans J.C., Beverstock G.C.et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood. 79:1992;1823-1828.
14. Saitoh K., Miura I., Takahashi N., Miura A.B. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood. 92:1998;2886-2892.
15. van Kamp H., Fibbe W.E., Jansen R.P., van der Keur M., de Graaff E., Willemze R.et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood. 80:1992;1774-1780.
16. Kroef M.J., Fibbe W.E., Mout R., Jansen R.P., Haak H.L., Wessels J.W.et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood. 81:1993;1849-1854.
17. Escudier S.M., Albitar M., Robertson L.E., Andreeff M., Pierce S., Kantarjian H.M. Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia. 10:1996;473-477.
18. Bonati A., Delia D., Starcich R. Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. Br. J. Haematol. 64:1986;487-491.
19. Ascensao J.L., Kay N.E., Wright J.J., Arthur D., Finkel B., Rydell R.et al. Lymphoblastic transformation of myelodysplastic syndrome. Am. J. Hematol. 22:1986;431-434.
20. Inoshita T. Acute lymphoblastic leukemia following myelodysplastic syndrome. Am. J. Clin. Pathol. 84:1985;233-237.
21. Heaney M.L., Golde D.W. Myelodysplasia. N. Engl. J. Med. 340:1999;1649-1660.
22. Cotran RS, Kumar V, Collins T. Robbins pathologic basis of disease. 6th ed. Philadelphia: Saunders, 1999.
23. Kouides P.A., Bennett J.M. Morphology and classification of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 6:1992;485-499.
24. Koeffler H.P., Golde D.W. Human preleukemia. Ann. Intern. Med. 93:1980;347-353.
25. Fialkow P.J. Clonal origin of human tumors. Biochim. Biophys. Acta. 458:1976;283-321.
26. Nowell P.C. Tumors as clonal proliferation. Virch. Arch. B Cell Pathol. 29:1978;145-150.
27. Raskind W.H., Tirumali N., Jacobson R., Singer J., Fialkow P.J. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood. 63:1984;1318-1323.
28. Raza A. Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns. Leuk. Res. 24:2000;63-72.
29. Raza A. Myelodysplastic syndromes may have an infectious etiology. J. Toxicol. Environ. Health A. 61:2000;387-390.
30. Lichtman M.A. Myelodysplasia or myeloneoplasia: thoughts on the nosology of clonal myeloid diseases. Blood Cells Mol. Dis. 26:2000;572-581.
31. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
32. Dickstein J.I., Vardiman J.W. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am. J. Clin. Pathol. 99:1993;513-525.
33. Harrison C.N., Gale R.E., Machin S.J., Linch D.C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 93:1999;417-424.
34. Michiels J.J. The myeloproliferative disorders. An historical appraisal and personal experiences. Leuk. Lymphoma. 22(Suppl. 1):1996;1-14.
35. Bennett C.L., Weinberg P.D., Lieberman J.J. Cancer insurance policies in Japan and the United States. West J. Med. 168:1998;17-22.
36. Jablonski S. Syndrome - a changing concept. Bull. Med. Libr. Assoc. 80:1992;323-327.
37. Greenberg P., Anderson J., de Witte T., Estey E., Fenaux P., Gupta P.et al. Problematic WHO re-classification of myelodysplastic syndromes. Members of the International MDS Study Group. J. Clin. Oncol. 18:2000;3447-3452.
38. Head D., Bennett J., Greenberg P., Hamblin T., Hasle H., Niemeyer C.et al. Classification of myelodysplastic syndrome: FAB versus WHO and pediatric MDS. Leuk. Res. 25:2001;S1.
39. Tefferi A., Mathew P., Noel P. The 5q- syndrome: a scientific and clinical update. Leuk. Lymphoma. 14:1994;375-378.
40. Germing U., Gattermann N., Aivado M., Hildebrandt B., Aul C. Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br. J. Haematol. 108:2000;724-728.
41. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk. Res. 24:2000;983-992.
42. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:1999;3835-3849.
43. Cassell EJ. The nature of suffering: and the goals of medicine. Oxford: Oxford University Press, 1994.
44. Tricot G.J. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk. Res. 16:1992;5-6.
45. Ost A., Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk. Res. 16:1992;9-11.
46. Culligan D.J., Jacobs A. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk. Res. 16:1992;4-5.
47. Farhi D.C. Bone marrow dysplasia. A continuing diagnostic challenge. Am. J. Clin. Pathol. 98:1992;473-475.
48. Ramos F., Fernandez-Ferrero S., Suarez D., Barbon M., Rodriguez J.A., Gil S.et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk. Res. 23:1999;283-290.
49. Gardais J. Dyshaemopoiesis in adults: a practical classification for diagnosis and management. Leuk. Res. 24:2000;641-651.
50. Bain B.J. The bone marrow aspirate of healthy subjects. Br. J. Haematol. 94:1996;206-209.
51. Champion K.M., Gilbert J.G., Asimakopoulos F.A., Hinshelwood S., Green A.R. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br. J. Haematol. 97:1997;920-926.
52. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F.et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 346:2002;564-569.
53. Imbert M., Scoazec J.Y., Mary J.Y., Jouzult H., Rochant H., Sultan C. Adult patients presenting with pancytopenia: a reappraisal of underlying pathology and diagnostic procedures in 213 cases. Hematol. Pathol. 3:1989;159-167.
54. Casagrande G., Michot F. Alcohol-induced bone marrow damage: status before and after a 4-week period of abstinence from alcohol with or without disulfiram. A randomized bone marrow study in alcohol-dependent individuals. Blut. 59:1989;231-236.
55. Rezuke W.N., Anderson C., Pastuszak W.T., Conway S.R., Firshein S.I. Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. Am. J. Hematol. 36:1991;291-293.
56. Karcher D.S., Frost A.R. The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. Am. J. Clin. Pathol. 95:1991;63-71.
57. Baurmann H., Schwarz T.F., Oertel J., Serke S., Roggendorf M., Huhn D. Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow. Ann. Hematol. 64:1992;43-45.
58. Hasle H., Heegaard E., Kerndrup G., Jensen I.M., Peterslund N.A., Hornsleth A. Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome. Leuk. Res. 20:1996;81-83.
59. Hofmann W.K., Ottmann O.G., Ganser A., Hoelzer D. Myelodysplastic syndromes: clinical features. Semin. Hematol. 33:1996;177-185.
60. Kampmeier P., Anastasi J., Vardiman J.W. Issues in the pathology of the myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 6:1992;501-522.
61. Bain B.J. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk. Lymphoma. 34:1999;443-449.
62. Neuwirtova R., Mocikova K., Musilova J., Jelinek J., Havlicek F., Michalova K.et al. Mixed myelodysplastic and myeloproliferative syndromes. Leuk. Res. 20:1996;717-726.
63. Tuzuner N., Cox C., Rowe J.M., Watrous D., Bennett J.M. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br. J. Haematol. 91:1995;612-617.
64. Barrett J. Myelodysplastic syndrome and aplastic anemia - diagnostic and conceptual uncertainties. Leuk. Res. 24:2000;595-596.
65. Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology. Semin. Hematol. 37:2000;15-29.
66. Appelbaum F.R., Barrall J., Storb R., Ramberg R., Doney K., Sale G.E.et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp. Hematol. 15:1987;1134-1139.
67. Graham D.L., Gastineau D.A. Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy. Am. J. Med. 93:1992;671-674.
68. Cermak J., Marinov Y., Jelinek J. CD59 and CD55 deficiency in patients with primary myelodysplastic syndrome: an analysis of 35 patients. Leuk. Res. 25:2001;S11-S12.
69. Okada M., Okamoto T., Takatsuka H., Wada H., Fujimori Y., Kakihsita E. Relationship between immunological abnormalities and paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndromes. Blood. 96:2000;149a.
70. Dhodapkar M.V., Li C.Y., Lust J.A., Tefferi A., Phyliky R.L. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance. Blood. 84:1994;1620-1627.
71. Hanson C.A., Dayharsh G.A., Morice W.G., Hodnefield J.M., Steensma D.P. Clonal T-cell and immunoglobulin gene rearrangements in myelodysplastic syndromes (MDS): a morphologic and immunoperoxidase study. Leuk. Res. 25:2001;S12-S13.
72. Greenberg P., Bishop M.R., Deeg H.J., Estey E., Erba H., Gore S.et al. NCCN practice guidelines for the myelodysplastic syndromes. Oncology. 12:1998;53-80.
73. Miyazato A., Ueno S., Ohmine K., Ueda M., Yoshida K., Yamashita Y.et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood. 98:2001;422-427.
74. van't Veer L.J., Dai H., van De Vijver M.J., He Y.D., Hart A.A., Mao M.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
75. Alizadeh A.A., Ross D.T., Perou C.M., van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol. 195:2001;41-52.
76. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
77. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R.et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Cooperative Group. Br. J. Haematol. 33:1976;451-458.
78. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R.et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189-199.
79. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br. J. Haematol. 87:1994;746-754.
80. Voglova J., Chrobak L., Neuwirtova R., Malaskova V., Straka L. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia - distinct subgroups or two stages of the same disease. Leuk. Res. 25:2001;493-499.
81. Germing U., Gattermann N., Minning H., Heyll A., Aul C. Problems in the classification of CMML - dysplastic versus proliferative type. Leuk. Res. 22:1998;871-878.
82. Michaux J.L., Martiat P. Chronic myelomonocytic leukaemia (CMML) - a myelodysplastic or myeloproliferative syndrome. Leuk. Lymphoma. 9:1993;35-41.
83. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G.et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
84. Rosati S., Mick R., Xu F., Stonys E., Le Beau M.M., Larson R.et al. Refractory cytopenia with multilineage dysplasia: further characterization of an unclassifiable myelodysplastic syndrome. Leukemia. 10:1996;20-26.
85. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 90:1997;2969-2977.
86. Bernstein S.H., Brunetto V.L., Davey F.R., Wurster-Hill D., Mayer R.J., Stone R.M.et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 14:1996;2486-2494.
87. Anonymous. The international statistical classification of diseases and related health problems. 10th revised ed. World Health Organisation, 1994.
88. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours: pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon: IARC, 2001.
89. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L.et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392.
90. Willis RA. Pathology of tumors. St. Louis: Mosby, 1948.
91. Koeppen H., Vardiman J.W. New entities, issues, and controversies in the classification of malignant lymphoma. Semin. Oncol. 25:1998;421-434.
92. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J. Lymphoma classification - from controversy to consensus: the REAL and WHO classification of lymphoid neoplasms. Ann. Oncol. 11:2000;3-10.
93. Michels S.D., Chan W., Jakubowski D., Vogler R. Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype. Lab. Invest. 62:1990;67a.
94. Balduini C.L., Guarnone R., Pecci A., Centenara E., Ascari E. Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes. Leukemia. 12:1998;1655-1656.
95. Garand R., Gardais J., Bizet M., Bremond J.L., Accard F., Callat M.P.et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk. Res. 16:1992;463-468.
96. Matsuda A., Jinnai I., Yagasaki F., Kusumoto S., Minamihisamatsu M., Honda S.et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia. 12:1998;482-485.
97. Bennett J.M., Brunning R.D., Vardiman J.W. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood. 99:2002;3074-3075.
98. Nosslinger T., Reisner R., Koller E., Gruner H., Tuchler H., Nowotny H.et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 98:2001;2935-2941.
99. Fenaux P., Beuscart R., Lai J.L., Jouet J.P., Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J. Clin. Oncol. 6:1988;1417-1424.
100. Estey E.H. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica. 83:1998;543-549.
101. Pedersen-Bjergaard J., Pedersen M., Roulston D., Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 86:1995;3542-3552.
102. Tricot G.J. Prognostic factors in the myelodysplastic syndromes. Leuk. Res. 16:1992;109-115.
103. Rowley J.D., Golomb H.M., Vardiman J.W. Non-random chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood. 58:1981;759-767.
104. Chen H., Sandler D.P., Taylor J.A., Shore D.L., Liu E., Bloomfield C.D.et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 347:1996;295-297.
105. Sasai Y., Horiike S., Misawa S., Kaneko H., Kobayashi M., Fujii H.et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk. Res. 23:1999;975-981.
106. Willman C. MDS/AML: models of genetic progression and clues to etiology. Leuk. Res. 25:2001;S1.
107. Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N.et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6:2000;4091-4095.
108. Rothman N., Smith M.T., Hayes R.B., Traver R.D., Hoener B., Campleman S.et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 57:1997;2839-2842.
109. Tsabouri S.E., Georgiou I., Alamanos I., Bourantas K.L. Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: a case-control study. Acta Haematol. 104:2000;169-173.
110. Willman CL. New insights into molecular genetics and biology of MDS. In: Proceedings of the 42nd Annual Meeting of the American Society of Hematology 2000, San Francisco, CA. American Society of Hematology, Washington, DC, 2000. p. 110-7.
111. Albitar M., Beran M., O'Brien S., Kantarjian H., Frieriech E., Keating M.et al. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood. 96:2000;372-373.
112. Sonneveld P., van Dongen J.J., Hagemeijer A., van Lom K., Nooter K., Schoester M.et al. High expression of the multidrug-resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia. 7:1993;963-969.
113. Schanz J., Wulich J., Fonatsch C., Haase D. Cytogenetic findings confirm that the prognostically relevant blast count threshold in MDS is at 10%. Blood. 96:2000;148a.
114. Sanz G.F., Sanz M.A., Vallespi T., Canizo M.C., Torrabadella M., Garcia S.et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395-408.
115. Rowley J.D. The role of chromosome translocations in leukemogenesis. Semin. Hematol. 36:1999;59-72.
116. Taj A.S., Ross F.M., Vickers M., Choudhury D.N., Harvey J.F., Barber J.C.et al. t(8;21) myelodysplasia, an early presentation of M2 AML. Br. J. Haematol. 89:1995;890-892.
117. Callat M.P., Contentin N., Buchonnet G., Borg J.Y., Fruchart C., Bastard C.et al. Translocation (8;21) does not mean necessarily an AML2. Leuk. Res. 25:2001;S32.
118. Haferlach T., Schoch C., Loffler H., Gassmann W., Schnittger S., Sauerland M.C.et al. Dysplastic features in 614 patients with de novo acute myeloid leukemia (AML): frequency, correlation to cytogenetic results and prognostic impact. Leuk. Res. 25:2001;S14.
119. Ballen K.K., Gilliland D.G., Kalish L.A., Shulman L.N. Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival. Cancer. 73:1994;314-321.
120. Lima C.S., Vassalo J., Lorand-Metze I., Bechelli A.P., Souza C.A. The significance of trilineage myelodysplasia in de novo acute myeloblastic leukemia: clinical and laboratory features. Haematologia. 28:1997;85-95.
121. Gahn B., Haase D., Unterhalt M., Drescher M., Schoch C., Fonatsch C.et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 10:1996;946-951.
122. Kahl C., Florschutz A., Muller G., Jentsch-Ullrich K., Arland M., Leuner S.et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann. Hematol. 75:1997;91-94.
123. Meckenstock G., Aul C., Hildebrandt B., Heyll A., Germing U., Wehmeier A.et al. Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance. Leuk. Lymphoma. 29:1998;523-531.
124. Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res, 2001;25:829-38.
125. Menke D.M., Colon-Otero G., Cockerill K.J., Jenkins R.B., Noel P., Pierre R.V. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am. J. Clin. Pathol. 98:1992;502-510.
126. Copplestone J.A., Mufti G.J., Hamblin T.J., Oscier D.G. Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy. Br. J. Haematol. 63:1986;149-159.
127. Greenberg B.R., Miller C., Cardiff R.D., MacKenzie M.R., Walling P. Concurrent development of preleukaemic, lymphoproliferative and plasma cell disorders. Br. J. Haematol. 53:1983;125-133.
128. List A.F., Gonzalez-Osete G., Kummet T., Doll D.C. Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am. J. Med. 90:1991;274-276.
129. Steensma D.P., Dewald G.W., Hodnefield J.M., Tefferi A., Hanson C.A. Clonal cytogenetic abnormalities suggestive of a myelodysplastic syndrome in patients with morphologically normal bone marrow aspirates. Blood. 96:2001;150a.
130. Cachia P.G., Taylor C., Thompson P.W., Tennant G.B., Masters G., Pettersson T.et al. Non-dysplastic myelodysplasia. Leukemia. 8:1994;677-681.
131. Castello A., Coci A., Magrini U. Paraneoplastic marrow alterations in patients with cancer. Haematologica. 77:1992;392-397.
132. Hasle H. Classification, epidemiology, and prognostic factors in childhood MDS. Leuk. Res. 25:2001;S9.
133. Hasle H, Bennett JM, et al. Consensus evidence-based classification of pediatric myelodysplasia, 2002 [in press].
134. Hofmann W.K., de Vos S., Hoelzer D., Wachsman W., Koeffler H.P. Myelodysplastic syndromes: defects in expression of genes involved in differentiation and cytoprotection of CD34+ cells as detected by oligonucleotide microarrays. Blood. 98:2001;729a.
135. Cole P., Sateren W., Delzell E. Epidemiologic perspectives on myelodysplastic syndromes and leukemia. Leuk. Res. 19:1995;361-365.
136. Maynadie M., Verret C., Moskovtchenko P., Mugneret F., Petrella T., Caillot D.et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br. J. Cancer. 74:1996;288-290.
137. Aul C., Bowen D.T., Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 83:1998;71-86.
138. Linman J.W., Bagby G.C. Jr. The preleukemic syndrome (hemopoietic dysplasia). Cancer. 42:1978;854-864.
139. Phillips M.J., Cull G.M., Ewings M. Establishing the incidence of myelodysplasia syndrome. Br. J. Haematol. 88:1994;896-897.
140. Williamson P.J., Kruger A.R., Reynolds P.J., Hamblin T.J., Oscier D.G. Establishing the incidence of myelodysplastic syndrome. Br. J. Haematol. 87:1994;743-745.
141. Anonymous. Surveillance, epidemiology, and end results (SEER) program public-use data (1973-1998). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2001.
142. Aul C., Gattermann N., Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk. Lymphoma. 16:1995;247-262.
143. Radlund A., Thiede T., Hansen S., Carlsson M., Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur. J. Haematol. 54:1995;153-156.
144. Aul C., Gattermann N., Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br. J. Haematol. 82:1992;358-367.
145. Aul C., Germing U., Gattermann N., Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious. Leuk. Res. 22:1998;93-100.
146. Reizenstein P., Dabrowski L. Increasing prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res. 11:1991;1069-1070.
147. Hellstrom Lindberg E., Hast R., Radlund A., Ost A. Incidence of myelodysplastic syndrome is increasing. Careful diagnosis is necessary for choice of the treatment. Lakartidningen. 91:1994;4253-4258.
148. Sanchez Fayos J., Outeirino Perez J.J., Prieto E., Roman A., Olavarria E., Cabello A.et al. Evolutive epidemiologic profile of myelodysplastic syndromes (1959-1993). Comparative study with acute myeloid leukemia and aplastic pancytopenias. Sangre (Barc). 39:1994;441-448.
149. McNally R.J., Roman E., Cartwright R.A. Leukemias and lymphomas: time trends in the UK, 1984-1993. Cancer Causes Control. 10:1999;35-42.
150. Bowen D.T., Jacobs A. Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects. J. Clin. Pathol. 42:1989;56-58.
151. Darrington D.L., Vose J.M., Anderson J.R., Bierman P.J., Bishop M.R., Chan W.C.et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J. Clin. Oncol. 12:1994;2527-2534.
152. Micallef I.N., Lillington D.M., Apostolidis J., Amess J.A., Neat M., Matthews J.et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J. Clin. Oncol. 18:2000;947-955.
153. Meza C., Gershwin M.E. Why is asthma becoming more of a problem. Curr. Opin. Pulm. Med. 3:1997;6-9.
154. Drexler H.G. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leuk. Res. 24:2000;109-115.
155. Anonymous. JCRB0092 [P39/TSU]. Japanese Cellular Research Bioresources Cell Bank, 2002.
156. Hassan Z., Fadeel B., Zhivotovsky B., Hellstrom-Lindberg E. Two pathways of apoptosis induced with all-trans-retinoic acid and etoposide in the myeloid cell line P39. Exp. Hematol. 27:1999;1322-1329.
157. Anzai N., Kawabata H., Hirama T., Masutani H., Ohmori M., Yoshida Y.et al. Marked apoptosis of human myelomonocytic leukemia cell line P39: significance of cellular differentiation. Leukemia. 8:1994;446-453.
158. Nagai M., Seki S., Kitahara T., Abe T., Minato K., Watanabe S.et al. A novel human myelomonocytoid cell line, P39/Tsugane, derived from overt leukemia following myelodysplastic syndrome. Gann. 75:1984;1100-1107.
159. Pedersen-Bjergaard J. Secondary MDS and AML, relationship between types of previous therapy and specific genetics and cytogenetics anormalities. Leuk Res 2001;25:S13.
160. Pedersen-Bjergaard J., Timshel S., Andersen M.K., Andersen A.S., Philip P. Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases. Genes Chromosomes Cancer. 23:1998;337-349.
161. Mecucci C., Rege-Cambrin G., Michaux J.L., Tricot G., Van den Berghe H. Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease. Br. J. Haematol. 64:1986;699-706.
162. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E.et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br. J. Haematol. 108:2000;346-356.
163. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosme aberrations in cancer. National Cancer Institute, 2001.
164. Block A.W., Carroll A.J., Hagemeijer A., Lm L.M., van Lom K., Olney H.J.et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 33:2002;401-412.
165. Konstantinopoulou V., Kamakari S., Ragoussis I., Anagnou N.P. Physical and hematopoietic transcript map of a 5q31 critical subregion associated with the 5q- syndrome. Leuk. Res. 25:2001;S3.
166. Jaju R.J., Boultwood J., Oliver F.J., Kostrzewa M., Fidler C., Parker N.et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer. 22:1998;251-256.
167. Legare R.D., Gribben J.G., Maragh M., Hermanowski-Vosatka A., Roach S., Tantravahi R.et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am. J. Hematol. 56:1997;45-51.
168. Schoch C., Schnittger S., Bursch S., Hiddemann W., Haferlach T. Resolving complex aberrant karyotypes in MDS and AML evolving from MDS with 24-color-FISH: a study of 40 cases. Leuk. Res. 25:2001;S2.
169. Mark H.F., Gray Y., Mark Y., Khorsand J., Sikov W. A multimodal approach in the diagnosis of patients with hematopoietic disorders. Cancer Genet. Cytogenet. 109:1999;14-20.
170. Ketterling RJ, Dewald GW. In: Steensma DP, editor. Results of M-FISH in 55 cases of cytogenetically normal MDS. Rochester, MN, 2001.
171. Dewald G., Hicks G., Higgins R., Griffin C., Cherry A., Rowe J.et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplasia: an Eastern Cooperative Oncology Group (ECOG) study. Blood. 96:2000;148a.
172. Garces C., Ruiz-Hidalgo M.J., Bonvini E., Goldstein J., Laborda J. Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk. Differentiation. 64:1999;103-114.
173. Ohno N., Izawa A., Hattori M., Kageyama R., Sudo T. Dlk inhibits stem cell factor-induced colony formation of murine hematopoietic progenitors: Hes-1-independent effect. Stem Cells. 19:2001;71-79.
174. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol. 19:2001;1405-1413.
175. Padua R.A., Guinn B.A., Al-Sabah A.I., Smith M., Taylor C., Pettersson T.et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 12:1998;887-892.
176. Misawa S., Horiike S. TP53 mutations in myelodysplastic syndrome. Leuk. Lymphoma. 23:1996;417-422.
177. Paquette R.L., Landaw E.M., Pierre R.V., Kahan J., Lubbert M., Lazcano O.et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 82:1993;590-599.
178. Ferrari T., Weber B., Pils S., Harbott J., Borkhardt A. Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7. Ann. Hematol. 80:2001;72-73.
179. Kakazu N., Taniwaki M., Horiike S., Nishida K., Tatekawa T., Nagai M.et al. Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes Cancer. 26:1999;336-345.
180. Nisse C., Haguenoer J.M., Grandbastien B., Preudhomme C., Fontaine B., Brillet J.M.et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br. J. Haematol. 112:2001;927-935.
181. Nisse C., Lorthois C., Dorp V., Eloy E., Haguenoer J.M., Fenaux P. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. Leukemia. 9:1995;693-699.
182. Bjork J., Albin M., Mauritzson N., Stromberg U., Johansson B., Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology. 11:2000;285-291.
183. Correa A., Mohan A., Jackson L., Perry H., Helzlsouer K. Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. I. Leukemias and myelodysplastic syndromes. Cancer Invest. 18:2000;366-380.
184. Nagata C., Shimizu H., Hirashima K., Kakishita E., Fujimura K., Niho Y.et al. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk. Res. 23:1999;57-62.
185. Bebshko V.G., Klymenko V.I., Bazika D.A., Cherviacova E.V., Kadnicova T.V., Sholoiko V.V. Cytogenetic and histologic characteristics of myelodysplastic syndrome at liquidators of consequences of the Chernobyl accident. Leuk. Res. 25:2001;S64.
186. Matsuo T., Tomonaga M., Bennett J.M., Kuriyama K., Imanaka F., Kuramoto A.et al. Re-classification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn. J. Clin. Oncol. 18:1988;91-96.
187. Kimura A., Takeuchi Y., Tanaka H., Satoh K., Ohtaki M., Hayakawa N. Atomic bomb radiation increases the risk of MDS. Leuk. Res. 25:2001;S13.
188. Mandla S.G., Goobie S., Kumar R.T., Hayne O., Zayed E., Guernsey D.L.et al. Genetic analysis of familial myelodysplastic syndrome: absence of linkage to chromosomes 5q31 and 7q22. Cancer Genet. Cytogenet. 105:1998;113-118.
189. Olopade O.I., Roulston D., Baker T., Narvid S., Le Beau M.M., Freireich E.J.et al. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 10:1996;669-674.
190. Grimwade D.J., Stephenson J., De Silva C., Dalton R.G., Mufti G.J. Familial MDS with 5q- abnormality. Br. J. Haematol. 84:1993;536-538.
191. Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M.et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 336:1997;1713-1720.
192. Alter B.P., Caruso J.P., Drachtman R.A., Uchida T., Velagaleti G.V., Elghetany M.T. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet. Cytogenet. 117:2000;125-131.
193. Aktas D., Koc A., Boduroglu K., Hicsonmez G., Tuncbilek E. Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. Cancer Genet. Cytogenet. 116:2000;44-46.
194. Iwahara Y., Ishii K., Watanabe S., Taguchi H., Hara H., Miyoshi I. Bloom's syndrome complicated by myelodysplastic syndrome and multiple neoplasia. Intern. Med. 32:1993;399-402.
195. Clark D.M., Lampert I.A. Apoptosis is a common histopathologic finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk. Lymphoma. 2:1990;415-418.
196. Raza A., Mundle S., Shetty V., Alvi S., Chopra H., Span L.et al. A paradigm shift in myelodysplastic syndromes. Leukemia. 10:1996;1648-1652.
197. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 7:1993;144-146.
198. Raza A., Alvi S., Borok R.Z., Span L., Parcharidou A., Alston D.et al. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leuk. Lymphoma. 27:1997;111-118.
199. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R.et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86:1995;268-276.
200. Lepelley P., Campergue L., Grardel N., Preudhomme C., Cosson A., Fenaux P. Is apoptosis a massive process in myelodysplastic syndromes. Br. J. Haematol. 95:1996;368-371.
201. Hellstrom-Lindberg E., Kanter-Lewensohn L., Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk. Res. 21:1997;415-425.
202. Reza S., Dar S., Andric T., Qawi H., Mundle S., Shetty V.et al. Biologic characteristics of 164 patients with myelodysplastic syndromes. Leuk. Lymphoma. 33:1999;281-287.
203. Parcharidou A., Raza A., Economopoulos T., Papageorgiou E., Anagnostou D., Papadaki T.et al. Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes. Eur. J. Haematol. 62:1999;19-26.
204. Shetty V., Hussaini S., Broady-Robinson L., Allampallam K., Mundle S., Borok R.et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood. 96:2000;1388-1392.
205. Parker J.E., Fishlock K.L., Mijovic A., Czepulkowski B., Pagliuca A., Mufti G.J. Low-risk myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br. J. Haematol. 103:1998;1075-1082.
206. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 96:2000;3932-3938.
207. Rajapaksa R., Ginzton N., Rott L.S., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 88:1996;4275-4287.
208. Greenberg P.L. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk. Res. 22:1998;1123-1136.
209. Mundle S.D., Mativi B.Y., Cartlidge J.D., Dangerfield B., Broady-Robinson L., Li B.et al. Signal antonym unique to myelodysplastic marrows correlates with altered expression of E2F1. Br. J. Haematol. 109:2000;376-381.
210. Davis R.E., Greenberg P.L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk. Res. 22:1998;767-777.
211. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y.et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 97:2001;1427-1434.
212. Allampallam K., Shetty V., Hussaini S., Mazzoran L., Zorat F., Huang R.et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 19:1999;5323-5328.
213. Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S.et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 20:1996;891-900.
214. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A.et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 103:1998;176-188.
215. Mundle S.D., Reza S., Ali A., Mativi Y., Shetty V., Venugopal P.et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 140:1999;201-207.
216. Gersuk G.M., Lee J.W., Beckham C.A., Anderson J., Deeg H.J. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood. 88:1996;1122-1123.
217. Fontenay-Roupie M., Bouscary D., Guesnu M., Picard F., Melle J., Lacombe C.et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br. J. Haematol. 106:1999;464-473.
218. Gupta P., Niehans G.A., LeRoy S.C., Gupta K., Morrison V.A., Schultz C.et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia. 13:1999;44-53.
219. Horikawa K., Nakakuma H., Kawaguchi T., Iwamoto N., Nagakura S., Kagimoto T.et al. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood. 90:1997;2716-2722.
220. Plasilova M., Zivny J., Jelinek J., Neuwirtova R., Cermak J., Necas E.et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 16:2002;67-73.
221. Zang D.Y., Goodwin R.G., Loken M.R., Bryant E., Deeg H.J. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood. 98:2001;3058-3065.
222. Cox T.C., Bottomley S.S., Wiley J.S., Bawden M.J., Matthews C.S., May B.K. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N. Engl. J. Med. 330:1994;675-679.
223. Cartwright G.E., Deiss A. Sideroblasts, siderocytes, and sideroblastic anemia. N. Engl. J. Med. 292:1975;185-193.
224. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk. Res. 24:2000;141-151.
225. Gattermann N., Retzlaff S., Wang Y.L., Hofhaus G., Heinisch J., Aul C.et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood. 90:1997;4961-4972.
226. Reddy P.L., Shetty V.T., Dutt D., York A., Dar S., Mundle S.D.et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br. J. Haematol. 116:2002;564-575.
227. Shetty V., Hussaini S., Alvi S., Joshi L., Shaher A., Dangerfield B.et al. Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cistern in bone marrow biopsies of myelodysplastic syndrome patients. Br. J. Haematol. 116:2002;817-825.
228. Shimada Y., Okuno S., Kawai A., Shinomiya H., Saito A., Suzuki M.et al. Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia. J. Hum. Genet. 43:1998;115-122.
229. Dewald G.W., Pierre R.V., Phyliky R.L. Three patients with structurally abnormal X chromosomes, each with Xq13 breakpoints and a history of idiopathic acquired sideroblastic anemia. Blood. 59:1982;100-105.
230. Dewald G.W., Brecher M., Travis L.B., Stupca P.J. Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. Cancer Genet. Cytogenet. 42:1989;173-185.
231. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int. J. Hematol. 72:2000;139-150.
232. Gordon M.S. Advances in supportive care of myelodysplastic syndromes. Semin. Hematol. 36:1999;21-24.
233. Raza A. Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group. Blood. 98:2001;251-252.
234. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D.et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 96:2000;3671-3674.
235. Steensma D.P., Letendre L., Tefferi A. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. Blood. 97:2001;3321-3322.
236. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br. J. Haematol. 89:1995;67-71.
237. Goy A., Belanger C., Casadevall N., Picard F., Guesnu M., Jaulmes D.et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br. J. Haematol. 84:1993;232-237.
238. Negrin R.S., Stein R., Doherty K., Cornwell J., Vardiman J., Krantz S.et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood. 87:1996;4076-4081.
239. Hellstrom-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J.et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br. J. Haematol. 99:1997;344-351.
240. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., Carlsson M., Carneskog J., Dahl I.M.et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 92:1998;68-75.
241. Economopoulos T., Mellou S., Papageorgiou E., Pappa V., Kokkinou V., Stathopoulou E.et al. Treatment of anemia in low-risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin. Leukemia. 13:1999;1009-1012.
242. Mantovani L., Lentini G., Hentschel B., Wickramanayake P.D., Loeffler M., Diehl V.et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br. J. Haematol. 109:2000;367-375.
243. Negrin R.S., Haeuber D.H., Nagler A., Kobayashi Y., Sklar J., Donlon T.et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 76:1990;36-43.
244. Yoshida Y., Nakahata T., Shibata A., Takahashi M., Moriyama Y., Kaku K.et al. Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome. Leuk. Lymphoma. 18:1995;457-463.
245. Thompson J.A., Lee D.J., Kidd P., Rubin E., Kaufmann J., Bonnem E.M.et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J. Clin. Oncol. 7:1989;629-637.
246. Kurzrock R., Cortes J., Thomas D.A., Jeha S., Pilat S., Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J. Clin. Oncol. 19:2001;4165-4172.
247. Hellstrom-Lindberg E., Kanter-Lewensohn L., Nichol J., Ost A. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway. Br. J. Haematol. 105:1999;966-973.
248. Ferrajoli A., Talpaz M., Kurzrock R., Harris D., Van Q., Estey E.H.et al. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation. Leuk. Lymphoma. 30:1998;279-292.
249. Gordon M.S., Nemunaitis J., Hoffman R., Paquette R.L., Rosenfeld C., Manfreda S.et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 85:1995;3066-3076.
250. Elias L., Hoffman R., Boswell S., Tensen L., Bonnem E.M. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes. I. Clinical results. Leukemia. 1:1987;105-110.
251. Nand S., Ellis T., Messmore H., Fisher S.G., Gaynor E., Fisher R.I. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Leukemia. 6:1992;220-223.
252. Holcombe R.F. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia. 7:1993;192-195.
253. Petti M.C., Latagliata R., Avvisati G., Spiriti M.A., Montefusco E., Spadea A.et al. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br. J. Haematol. 95:1996;364-367.
254. Stone R.M., Spriggs D.R., Arthur K.A., Mayer R.J., Griffin J., Kufe D.W. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am. J. Clin. Oncol. 16:1993;159-163.
255. Schwarzinger I., Stain C., Bettelheim P., Hinterberger W., Lechner K. Gamma-interferon in myelodysplastic syndromes: a pilot study. Oncology. 47:1990;322-326.
256. Maiolo A.T., Cortelezzi A., Calori R., Polli E.E. Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group. Leukemia. 4:1990;480-485.
257. Miller A.M., Noyes W.E., Taetle R., List A.F. Limited erythropoietic response to combined treatment with recombinant human interleukin-3 and erythropoietin in myelodysplastic syndrome. Leuk. Res. 23:1999;77-83.
258. Nand S., Sosman J., Godwin J.E., Fisher R.I. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood. 83:1994;357-360.
259. Nimer S.D., Paquette R.L., Ireland P., Resta D., Young D., Golde D.W. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp. Hematol. 22:1994;875-880.
260. Kurzrock R., Talpaz M., Estrov Z., Rosenblum M.G., Gutterman J.U. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J. Clin. Oncol. 9:1991;1241-1250.
261. Ganser A., Seipelt G., Verbeek W., Ottmann O.G., Maurer A., Kolbe K.et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia. 8:1994;369-375.
262. Hofmann W.K., Ganser A., Seipelt G., Ottmann O.G., Zander C., Geissler G.et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans-retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann. Hematol. 78:1999;125-130.
263. Santini V., Ferrini P.R. Differentiation therapy of myelodysplastic syndromes: fact or fiction. Br. J. Haematol. 102:1998;1124-1138.
264. Besa E.C., Kunselman S., Nowell P.C. A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. The Central Pennsylvania Oncology Group. Leuk. Res. 22:1998;741-749.
265. de Witte T., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M.et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia. 9:1995;1805-1811.
266. Ruutu T., Hanninen A., Jarventie G., Koistinen P., Koivunen E., Katka K.et al. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk. Res. 21:1997;133-138.
267. Economopoulos T., Papageorgiou E., Stathakis N., Constantinidou M., Parharidou A., Kostourou A.et al. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk. Res. 20:1996;385-390.
268. Bennett J.M., Young M.S., Liesveld J.L., Paietta E., Miller K.B., Lazarus H.M.et al. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. Am. J. Hematol. 66:2001;23-27.
269. Cheson B.D., Zwiebel J.A., Dancey J., Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin. Oncol. 27:2000;560-577.
270. Estey E.H., Thall P.F., Pierce S., Cortes J., Beran M., Kantarjian H.et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans-retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 93:1999;2478-2484.
271. Ferrara F., Leoni F., Pinto A., Mirto S., Morra E., Zagonel V.et al. Fludarabine, cytarabine, and granulocyte colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer. 86:1999;2006-2013.
272. Carella A.M., Cascavilla N., Greco M.M., Melillo L., Sajeva M.R., Ladogana S.et al. Treatment of poor risk acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk. Lymphoma. 40:2001;295-303.
273. Doll D.C., Kasper L.M., Taetle R., List A.F. Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. Leuk. Res. 22:1998;7-12.
274. Wattel E., Guerci A., Hecquet B., Economopoulos T., Copplestone A., Mahe B.et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood. 88:1996;2480-2487.
275. Oscier D.G., Worsley A., Hamblin T.J., Mafti G.J. Treatment of chronic myelomonocytic leukemia with low dose etoposide. Br. J. Haematol. 72:1989;468-471.
276. Denzlinger C., Bowen D., Benz D., Gelly K., Brugger W., Kanz L. Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia. Br. J. Haematol. 108:2000;93-95.
277. Bowen D.T., Gelly K., Groves M., Conningham J., Kerr R., Sales M. The evolving ethical dilemma of low dose melphalan chemotherapy in advanced MDS/AML: quality of life in remission versus predictable induction of 17p deletion. Leuk. Res. 25:2001;S65.
278. Miller K.B., Kim K., Morrison F.S., Winter J.N., Bennett J.M., Neiman R.S.et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann. Hematol. 65:1992;162-168.
279. Cheson B.D. The maturation of differentiation therapy. N. Engl. J. Med. 327:1992;422-424.
280. Rowinsky E.K., Conley B.A., Jones R.J., Spivak J.L., Auerbach M., Donehower R.C. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of 5-day exposure to maximal therapeutic concentrations. Leukemia. 6:1992;526-534.
281. Andreeff M., Stone R., Michaeli J., Young C.W., Tong W.P., Sogoloff H.et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 80:1992;2604-2609.
282. Feldman E.J., Seiter K.P., Ahmed T., Baskind P., Arlin Z.A. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia. 10:1996;40-42.
283. Gore S.D., Baylin S.B., Herman J.G., Miller C.B. Clinical development of histone deacetylase inhibitors for the treatment of MDS and resistant myeloid malignancies. Leuk. Res. 25:2001;S22.
284. Timonen T.T., Kauma H. Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur. J. Haematol. 49:1992;234-238.
285. Ruutu T., Volin L., Tenhunen R. Haem arginate as a treatment for myelodysplastic syndromes. Br. J. Haematol. 65:1987;425-428.
286. Volin L., Ruutu T., Knuutila S., Tenhunen R. Heme arginate treatment for myelodysplastic syndromes. Leuk. Res. 12:1988;423-431.
287. Stone R.M. Bryostatin 1: differentiating agent from the depths. Leuk. Res. 21:1997;399-401.
288. Hofmann W.K., Kell W.J., Fenaux P., Castaigne S., Ganser A., Chomienne C.et al. Oral 9-cis-retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. Leukemia. 14:2000;1583-1588.
289. Venditti A., Tamburini A., Buccisano F., Scimo M.T., Del Poeta G., Maurillo L.et al. A phase II trial of all-trans-retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Ann. Hematol. 79:2000;138-142.
290. Letendre L., Noel P., White W.L., Tefferi A., Litzow M.R., Li C.Y.et al. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C. Leuk. Res. 23:1999;811-815.
291. Nair R., Nair C.N., Advani S.H. All-trans-retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome. Leuk. Lymphoma. 29:1998;187-192.
292. Letendre L., Levitt R., Pierre R.V., Schroeder G., Krook J.A., Mailliard J.E.et al. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am. J. Hematol. 48:1995;233-236.
293. List A.F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R.et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364-3369.
294. Hofmann W.K., Seipelt G., Ottmann O.G., Kalina U., Koschmieder S., Brucher J.et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann. Hematol. 79:2000;255-258.
295. Tefferi A., Elliott M.A., Steensma D.P., Hook C.C., Dispenzieria A., Hanson C.A.et al. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk. Res. 25:2001;183-185.
296. Kornblith A.B., Herndon J.E. II, Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F.et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 20:2002;2441-2452.
297. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M.et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956-962.
298. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50:2000;229-235.
299. Stasi R., Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br. J. Haematol. 116:2002;334-337.
300. Nemunaitis J., Rosenfeld C., Getty L., Boegel F., Meyer W., Jennings L.W.et al. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am. J. Clin. Oncol. 18:1995;189-193.
301. Raza A., Qawi H., Lisak L., Andric T., Dar S., Andrews C.et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 95:2000;1580-1587.
302. Bouscary D., Chen Y.L., Guesnu M., Picard F., Viguier F., Lacombe C.et al. Activity of the caspase-3/CPP32 enzyme is increased in early stage myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp. Hematol. 28:2000;784-791.
303. Boudard D., Sordet O., Vasselon C., Revol V., Bertheas M.F., Freyssenet D.et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia. 14:2000;2045-2051.
304. Mundle S.D., Shetty V.T., Raza A. Caspases and apoptosis in myelodysplastic syndromes. Exp. Hematol. 28:2000;1310-1312.
305. Biesma D.H., van den Tweel J.G., Verdonck L.F. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 79:1997;1548-1551.
306. Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol. 99:1997;699-705.
307. Tichelli A., Gratwohl A., Wuersch A., Nissen C., Speck B. Antilymphocyte globulin for myelodysplastic syndrome. Br. J. Haematol. 68:1988;139-140.
308. Jonasova A., Neuwirtova R., Cermak J., Vozobulova V., Mocikova K., Siskova M.et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 100:1998;304-309.
309. Catalano L., Selleri C., Califano C., Luciano L., Volpicelli M., Rocco S.et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica. 85:2000;133-138.
310. Noel P. Management of patients with myelodysplastic syndromes. Mayo Clin. Proc. 66:1991;485-497.
311. Cafolla A., Dragoni F., Girelli G., Tosti M.E., Monarca B., Kendall R.et al. Red cell folate in elderly patients with myelodysplastic syndrome. Eur. J. Haematol. 61:1998;160-163.
312. Najean Y., Pecking A. Refractory anaemia with excess of myeloblasts in the bone marrow: a clinical trial of androgens in 90 patients. Br. J. Haematol. 37:1977;25-33.
313. Najean Y., Pecking A. Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias. Cancer. 44:1979;1976-1982.
314. Chabannon C., Molina L., Pegourie-Bandelier B., Bost M., Leger J., Hollard D. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer. 73:1994;3073-3080.
315. Chan G.W., DiVenuti G., Miller K.B. Danazol for the treatment of thrombocytopenia in myelodysplastic syndrome. Blood. 96:2000;147a.
316. Wattel E., Cambier N., Caulier M.T., Sautiere D., Bauters F., Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br. J. Haematol. 87:1994;205-208.
317. Buzaid A.C., Garewal H.S., Lippman S.M., Durie B.G., Katakkar S.B., Greenberg B.R. Danazol in the treatment of myelodysplastic syndromes. Eur. J. Haematol. 39:1987;346-348.
318. Nakagawa M., Terashima T., D'Yachkova Y., Bondy G.P., Hogg J.C., van Eeden S.F. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation. 98:1998;2307-2313.
319. Bagby G.C. Jr., Gabourel J.D., Linman J.W. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in vitro techniques. Ann. Intern. Med. 92:1980;55-58.
320. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T.et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br. J. Haematol. 94:1996;288-299.
321. Kontoghiorghes G.J., Bartlett A.N., Hoffbrand A.V., Goddard J.G., Sheppard L., Barr J. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br. J. Haematol. 76:1990;295-300.
322. Darley R.L., Hoy T.G., Baines P., Padua R.A., Burnett A.K. Mutant N-ras induces erythroid lineage dysplasia in human CD34+ cells. J. Exp. Med. 185:1997;1337-1347.
323. Karp J.E., Lancet J.E., Kaufmann S.H., End D.W., Wright J.J., Bol K.et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369.
324. Donelli A., Chiodino C., Panissidi T., Roncaglia R., Torelli G. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes. Haematologica. 85:2000;1002-1003.
325. Gallagher R.E. Arsenic - new life for an old potion. N. Engl. J. Med. 339:1998;1389-1391.
326. Giles F.J., Cortes J.E., Baker S.D., Thomas D.A., O'Brien S., Smith T.L.et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J. Clin. Oncol. 19:2001;762-771.
327. Rivera C.E., Krueger L.A., Mayo D.J., Arthur D.C. Experimental treatment with transfusion dependent 5q- syndrome with leucovorin. Blood. 96:2000;263b.
328. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M.et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042.
329. Hales B.F. Thalidomide on the comeback trail. Nat. Med. 5:1999;489-490.
330. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P.et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341:1999;1565-1571.
331. Raje N., Anderson K. Thalidomide - a revival story. N. Engl. J. Med. 341:1999;1606-1609.
332. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F.et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 98:2001;958-965.
333. Raza A., Lisak L., Little L., Ekbal M., du Rant M., Ali E.et al. Thalidomide as a single agent or in combination with topotecan, pentoxifylline, and/or enbrel in myelodysplastic syndromes (MDS). Blood. 96:2000;146a.
334. Strupp C., Germing U., Aivado M., Misgeld E., Hildebrandt B., Haas R.et al. Thalidomide for the treatment of myelodysplastic syndromes (MDS). Leuk. Res. 25:2001;S69.
335. Musto P., Scalzulli P.R., Bodenizza C., Falcone A., Sanpaolo G., D'Arena G.et al. Thalidomide therapy for myelodysplastic syndromes. Leuk. Res. 25:2001;S68.
336. Anonymous. STEPS™: system for thalidomide education and prescribing safety. Celgene, 2001.
337. Castilla E.E., Ashton-Prolla P., Barreda-Mejia E., Brunoni D., Cavalcanti D.P., Correa-Neto J.et al. Thalidomide, a current teratogen in South America. Teratology. 54:1996;273-277.
338. Anderson J.E. Bone marrow transplantation for myelodysplasia. Blood Rev. 14:2000;63-77.
339. De Witte T. Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias. Int. J. Hematol. 72:2000;151-156.
340. Molassiotis A., Morris P.J. Suicide and suicidal ideation after marrow transplantation. Bone Marrow Transplant. 19:1997;87-90.
341. Deeg H.J., Shulman H.M., Anderson J.E., Bryant E.M., Gooley T.A., Slattery J.T.et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 95:2000;1188-1194.
342. Sutton L., Chastang C., Ribaud P., Jouet J.P., Kuentz M., Attal M.et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 88:1996;358-365.
343. Castro-Malaspina H., Harris R.E., Gajewski J., Ramsay N., Collins R., Dharan B.et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 99:2002;1943-1951.
344. Jurado M., Deeg H.J., Storer B., Anasetti C., Anderson J.E., Bryant E.et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable non-relapse mortality. Biol. Blood Marrow Transplant. 8:2002;161-169.
345. Anderson J.E., Appelbaum F.R., Schoch G., Gooley T., Anasetti C., Bensinger W.I.et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 87:1996;51-58.
346. de Witte T., Hermans J., Vossen J., Bacigalupo A., Meloni G., Jacobsen N.et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 110:2000;620-630.
347. Oosterveld M., de Witte T. Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. Blood Rev. 14:2000;182-189.
348. Carella A.M., Dejana A., Lerma E., Podesta M., Benvenuto F., Chimirri F.et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br. J. Haematol. 95:1996;127-130.
349. Anan K., Ito M., Misawa M., Ohe Y., Kai S., Kohsaki M.et al. Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene. Br. J. Haematol. 89:1995;838-844.
350. Culligan D.J., Bowen D.T., May A., White D., Padua R.A., Burnett A.K. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. Br. J. Haematol. 89:1995;675-677.
351. Delforge M., Demuynck H., Verhoef G., Vandenberghe P., Zachee P., Maertens J.et al. Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br. J. Haematol. 102:1998;486-494.
352. Ito T., Ohashi H., Kagami Y., Ichikawa A., Saito H., Hotta T. Recovery of polyclonal hematopoiesis in patients with myelodysplastic syndromes following successful chemotherapy. Leukemia. 8:1994;839-843.
353. Mijovic A., Delforge M., Sekhavat M., Czepulkowski B., Mufti G.J. Do patients with low-grade myelodysplastic syndrome mobilise normal hemopoietic progenitors. Leuk. Res. 25:2001;S4.
354. De Witte T. Prognostic factors in autologous stem cell transplantation (ASCT) for patients with MDS and AML following MDS. Leuk. Res. 25:2001;S3.
355. Wattel E., Solary E., Leleu X., Dreyfus F., Brion A., Jouet J.P.et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia. 13:1999;524-529.
356. Barrett J., Childs R. Non-myeloablative stem cell transplants. Br. J. Haematol. 111:2000;6-17.
357. Parker J.E., Shafi T., Mijovic A., Devereux S., Pagliuca A., Garg M.et al. Allogeneic stem cell transplantation (SCT) in MDS: interim results of outcome following non-myeloablative conditioning compared to standard preparative regimens. Leuk. Res. 25:2001;S21.
358. Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. N. Engl. J. Med. 344:2001;1860-1861.
359. Laughlin M.J., Barker J., Bambach B., Koc O.N., Rizzieri D.A., Wagner J.E.et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J. Med. 344:2001;1815-1822.
360. Pecora A.L. Progress in clinical application of use of progenitor cells expanded with hematopoietic growth factors. Curr. Opin. Hematol. 8:2001;142-148.
361. Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 59:1985;425-433.
362. Greenberg P. Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. Lancet. 357:2001;1059-1060.
363. Tien H.F., Tang J.H., Tsay W., Liu M.C., Lee F.Y., Wang C.H.et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 112:2001;148-454.
364. Ohyashiki J.H., Iwama H., Yahata N., Ando K., Hayashi S., Shay J.W.et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin. Cancer Res. 5:1999;1155-1160.
365. Shimazaki K., Ohshima K., Suzumiya J., Kawasaki C., Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br. J. Haematol. 110:2000;584-590.
366. Mangi M.H., Mufti G.J. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood. 79:1992;198-205.
367. Lambertenghi Deliliers G., Annaloro C., Soligo D., Oriani A. The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. Leuk. Lymphoma. 28:1998;231-239.
368. de Souza Fernandez T., Ornellas M.H., Otero de Carvalho L., Tabak D., Abdelhay E. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk. Res. 24:2000;839-848.
369. Mauritzson N., Johansson B., Rylander L., Albin M., Stromberg U., Billstrom R.et al. The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex. Br. J. Haematol. 113:2001;347-356.
370. Doll D.C., List A.F. Myelodysplastic syndromes: introduction. Semin. Oncol. 19:1992;1-3.
371. Noel P., Solberg L.A. Jr. Myelodysplastic syndromes: pathogenesis, diagnosis and treatment. Crit. Rev. Oncol. Hematol. 12:1992;193-215.
372. Luzzatto A.M. Sull' anemia grave megaloblastica senza reporto ematologico corrispondente (anemia pseudoaplastica). Riv. Veneta di sc. Med. Venezia. 47:1907;193-212.
373. Rhoads C.P., Barker W.H. Refractory anemia: analysis of 100 cases. JAMA. 110:1938;794.
374. Chevallier P. Sur la terminologie des leucoses et les affections-frontieres: les odoleucoses. Anémies réfractaires: Enzymopathies acquises des cellules souches hématopoïétiques 1942;15:587-93.
375. Hamilton-Paterson J.L. Preleukaemic anaemia. Acta Haematol. (Basel). 2:1949;309-316.
376. Block M., Jacobson L.O., Bethard W.F. Preleukemic acute human leukemia. JAMA. 152:1953;1018-1028.
377. Bjorkman S.E. Chronic refractory anemia with sideroblastic bone marrow: a study of four cases. Blood. 11:1956;250-259.
378. Dacie J.V., Smith M.D., White J.C., Mollin D.L. Refractory normoblastic anaemia: a clinical and haematological study of seven cases. Br. J. Haematol. 5:1959;56-82.
379. Rheingold J.J., Kaufman R., Adelson E., Lear A. Smoldering acute leukemia. N. Engl. J. Med. 268:1963;812-815.
380. Dameshek W. The DiGuglielmo syndrome revisited. Blood. 34:1969;567-572.
381. Dreyfus B, Rochant H, Sultan C. Le Sang: Biologie & Pathologie (Paris). Nouv Rev Fr Hematol 1969;9:65-86.
382. Dreyfus B, Rochant H, Sultan C, Clauvel JP, Yvart J, Chesneau AM. Lesanémies refractaires avec excés de myéloblastes dans la moelle: Étude de onze Obser vationes. Presse Med 1970;78:359-64.
383. Zittoun R, Bernadou A, Bilski-Pasquier G, Bousser J. Les Leucemies myelo-monocytaires subaigues. Etude de 27 caset revue de la litterature. Sem Hop 1972;48:1943-56.
384. Lehrer R.I., Goldberg L.S., Apple M.A., Rosenthal N.P. Refractory megaloblastic anemia with myeloperoxidase-deficient neutrophils. Ann. Intern. Med. 76:1972;447-453.
385. Saarni M.I., Linman J.W. Preleukemia: the hematologic syndrome preceding acute leukemia. Am. J. Med. 55:1973;38-48.
386. Miescher P.A., Farquet J.J. Chronic myelomonocytic leukemia in adults. Semin. Hematol. 11:1974;129-139.
387. Beard M.E., Bateman C.J., Crowther D.C., Wrigley P.F., Whitehouse J.M., Fairley G.H.et al. Hypoplastic acute myelogenous leukaemia. Br. J. Haematol. 31:1975;167-176.
388. Streuli R.A., Testa J.R., Vardiman J.W., Mintz U., Golomb H.M., Rowley J.D. Dysmyelopoietic syndrome: sequential clinical and cytogenetic studies. Blood. 55:1980;636-644.